FDA to develop new framework for opioid analgesics following AcelRx approval

FDA to develop new framework for opioid analgesics following AcelRx approval

Source: 
Drug Delivery Business News
snippet: 

The FDA last week approved AcelRx‘s (NSDQ:ACRX) Dsuvia sufentanil product, noting that use of the opioid will be tightly restricted to adults experiencing acute pain in medically-supervised healthcare settings.